+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Autologous Cell Therapies Market by Therapy Area, Cell Type, Source Tissue, Process Technology, End User - Global Forecast to 2030- Product Image
Autologous Cell Therapies Market by Therapy Area, Cell Type, Source Tissue, Process Technology, End User - Global Forecast to 2030- Product Image
Sale

Autologous Cell Therapies Market by Therapy Area, Cell Type, Source Tissue, Process Technology, End User - Global Forecast to 2030

  • PDF Icon

    Report

  • 188 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5887813
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Autologous Cell Therapies Market grew from USD 9.24 billion in 2024 to USD 10.62 billion in 2025. It is expected to continue growing at a CAGR of 14.63%, reaching USD 20.99 billion by 2030.

Embarking on the Next Frontier in Autologous Cell Treatment

The landscape of autologous cell therapies stands at a pivotal juncture where scientific breakthroughs converge with growing clinical adoption. As patients and practitioners seek personalized treatment modalities, harnessing the power of one’s own cells has transformed from a nascent concept into a robust field offering hope across a range of indications. This executive summary maps the key drivers propelling this evolution, underscores the strategic disruptions reshaping industry dynamics, and outlines the framework of our analysis.

Over the past decade, advancements in cell processing, genetic engineering, and manufacturing scale‐up have accelerated pipelines and paved the way for regulatory approvals. Simultaneously, stakeholder collaboration-from academic pioneers to contract developers-has fostered an ecosystem capable of addressing complex logistical and technical hurdles. As we embark on this deep dive, readers will gain clarity on emerging trends, regional variances, segmentation nuances, and actionable strategies essential for navigating the next wave of growth in autologous cell therapies.

Unveiling Transformative Shifts Revolutionizing the Landscape

An unprecedented convergence of scientific innovation and commercial momentum has catalyzed transformative shifts in the autologous cell therapy landscape. First, the maturation of gene editing and vector design has elevated therapeutic precision, enabling customized modifications that enhance safety and efficacy. Concurrently, modular manufacturing platforms have reduced production timelines and costs, creating pathways for decentralization and wider clinical access.

Across research and clinical networks, digital integration and data analytics are further revolutionizing patient stratification and real-time monitoring of cell performance. By leveraging advanced bioprocess control systems and machine learning algorithms, developers can optimize yield, consistency, and product quality. These shifts are not isolated; they interlock to reshape traditional R&D paradigms, spur competitive alliances, and unlock new revenue channels. In this section, we explore how these disruptive forces converge to redefine value creation and propel autologous therapies into mainstream practice.

Deciphering the Cumulative Impact of 2025 US Tariffs

The imposition of revised tariffs on biomanufacturing inputs, cell processing reagents, and ancillary equipment in 2025 has introduced a complex layer of cost pressure for stakeholders in the autologous cell therapy domain. Raw material sourcing, which once relied heavily on cross-border trade, now contends with elevated duties that ripple across supply chains. Clinics and contract manufacturers face recalibrated procurement strategies to mitigate margin erosion, while developers reassess their ingredient portfolios and consider alternative regional suppliers.

Beyond simple cost adjustments, the tariff landscape is catalyzing strategic realignments. Organizations are accelerating local capacity expansions to insulate operations from fluctuating import duties and to shorten lead times. At the policy level, advocacy for performance-based exemptions is gaining traction, highlighting cell therapies’ potential to reduce overall healthcare expenditure by delivering durable patient outcomes. This section dissects how these tariff dynamics influence pricing models, competitive positioning, and the broader investment climate.

Illuminating Market Segmentation Driving Strategic Insights

A granular understanding of market segmentation is vital for aligning R&D pipelines, manufacturing assets, and go-to-market strategies with therapeutic demand. Analysis by therapy area reveals that wound healing applications within dermatology are driving early commercial momentum, while autoimmune disease interventions and transplant rejection prophylaxis in immunology attract significant research investment. Neurology programs targeting Parkinson’s disease and spinal cord injury are gathering clinical validation, even as oncology portfolios span hematological malignancies and solid tumors, each with distinct regulatory pathways and efficacy benchmarks. Orthopedic initiatives focused on bone regeneration and cartilage repair are emerging as strategic growth pillars, leveraging advances in scaffold design and cell differentiation protocols.

When dissecting by cell type, stem cells occupy a dominant share, with hematopoietic, induced pluripotent, and mesenchymal lineages each offering unique therapeutic windows. NK cell approaches, particularly CAR NK constructs, and engineered T cell platforms such as CAR T and TCR T are rapidly maturing, propelled by favorable safety profiles and scalable manufacturing platforms. Source tissue remains a fundamental differentiator; adipose tissue and bone marrow continue to serve as primary harvest sites, complemented by cord blood and peripheral blood collections that facilitate off-the-shelf applications. Process technology segmentation highlights critical workflow stages: isolation techniques establish purity standards, expansion systems scale cell populations, formulation methods-encompassing cryopreservation and lyophilization-extend shelf life, and genetic modification strategies leverage both viral vectors and non-viral techniques to confer precise functional attributes. Finally, the end-user landscape spans contract development and manufacturing organizations optimizing production services, hospitals deploying therapies through academic medical centers and community facilities, research institutes driving translational studies, and specialty clinics delivering niche regenerative treatments.

Unraveling Regional Dynamics Shaping Market Growth

Regional dynamics exert a profound influence on autologous cell therapy adoption, infrastructure development, and regulatory evolution. In the Americas, progressive frameworks and robust funding pipelines have positioned the United States as a global leader, while Latin American markets are emerging through targeted public-private collaborations that expand clinical trial networks. Europe, the Middle East and Africa present a diverse tapestry of regulatory regimes: centralized EMA approvals coexist with innovative fast-track pathways in select Middle Eastern states, even as EMEA’s expanding manufacturing hubs cater to pan-regional demand and leverage cost differentials in specialized economies.

Across Asia-Pacific, rapid uptake is driven by a combination of governmental incentives, growing biotechnology clusters, and strategic investments in both academic research and commercial GMP facilities. Regional harmonization efforts, particularly within Southeast Asian alliances, aim to streamline clinical data sharing and regulatory alignment. As these geographies mature, cross-border partnerships and licensing agreements will continue to shape market entry strategies, with each region’s unique ecosystem offering differentiated risk-reward profiles for stakeholders.

Spotlight on Leading Innovators and Strategic Players

Leading biopharma and specialized cell therapy pioneers are defining competitive benchmarks through integrated value chains, diversified pipelines, and strategic collaborations. Established multinational corporations leverage deep pockets to acquire promising cell therapy platforms and to build global manufacturing footprints that ensure supply security. Mid-size innovators focus on niche indications, advancing proprietary vectors and cell engineering techniques that offer clear differentiation in clinical performance or safety.

Contract development and manufacturing organizations are expanding capabilities to serve as full-service partners, spanning process development to commercial scale-up, while technology providers supply modular bioreactor systems and digital monitoring tools essential for optimized production. Moreover, emerging biotech firms are disrupting traditional models through partnerships with academic centers, enabling rapid bench-to-clinic translation. Across this competitive spectrum, agility in regulatory strategy, IP positioning, and supply chain resilience distinguishes the most influential players, setting the stage for industry consolidation and long-term value creation.

Actionable Strategies for Industry Leadership and Growth

To navigate the evolving autologous cell therapy arena, industry leaders must adopt a multi-pronged approach that balances innovation with operational excellence. First, investing in modular, decentralized manufacturing infrastructure will reduce lead times and mitigate tariff-related supply risks. Stakeholders should also pursue strategic alliances with reagent suppliers and logistics partners to secure favorable procurement agreements and distribution networks.

Second, prioritizing flexible regulatory engagement through early dialogue with authorities will streamline approval pathways, particularly for combination products and novel genetic constructs. Concurrently, integrating digital platforms for real-time process analytics and patient monitoring can elevate quality control standards and accelerate market entry. Third, a nuanced portfolio management strategy-allocating resources across high-potential therapy areas, cell types, and geographies-will maximize return on investment while hedging against clinical or policy uncertainties. Finally, fostering cross-sector collaborations, including academic partnerships and consortium-based research initiatives, will sustain innovation pipelines and expand access to critical expertise.

Robust Research Methodology Underpinning Our Analysis

This analysis synthesizes secondary data from peer-reviewed journals, patent filings, regulatory databases, and corporate disclosures, complemented by primary interviews with key opinion leaders, bioprocess engineers, and commercial executives. We employed a triangulation methodology to validate historical case studies and to map emerging trends against quantitative performance metrics. Therapy area and technology segmentation frameworks were developed through a bottom-up approach, correlating clinical pipeline schedules with manufacturing capacity forecasts.

Regional insights derive from a combination of regulatory document reviews, in-market stakeholder consultations, and field surveys conducted across major hubs. Cost impact analysis of tariff changes incorporates import duty schedules, supplier pricing data, and scenario modeling to assess sensitivity across key inputs. Company profiling leveraged deal databases, funding round announcements, and expert assessments to rank competitive positioning. The result is a robust, multi-dimensional dataset designed to inform strategic decision-making at every stage of the autologous cell therapy value chain.

Concluding Insights and Pathways to Advancement

Autologous cell therapies stand on the cusp of a new era defined by personalized treatment paradigms, distributed manufacturing networks, and regulatory frameworks that balance innovation with patient safety. The convergence of technological advancements, tariff-influenced supply chain realignments, and region-specific market dynamics underscores the complexity inherent in this field. Yet within complexity lies opportunity: stakeholders who can deftly navigate segmentation intricacies, align portfolio strategies with regional ecosystems, and leverage collaborative partnerships will capture disproportionate value.

As the market matures, sustained success will hinge on agility, foresight, and a commitment to continuous learning. The insights presented in this summary chart a course for organizations seeking to lead the next wave of autologous cell therapy breakthroughs. Ultimately, the capacity to transform cutting-edge science into scalable, accessible treatments will define the winners in this rapidly evolving domain.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Therapy Area
    • Dermatology
      • Wound Healing
    • Immunology
      • Autoimmune Diseases
      • Transplant Rejection
    • Neurology
      • Parkinsons Disease
      • Spinal Cord Injury
    • Oncology
      • Hematological Cancer
      • Solid Tumors
    • Orthopedics
      • Bone Regeneration
      • Cartilage Repair
  • Cell Type
    • Dendritic Cells
    • Nk Cells
      • Car Nk
    • Stem Cells
      • Hematopoietic Stem
      • Ipsc
      • Mesenchymal Stem
    • T Cells
      • Car T
      • Tcr T
  • Source Tissue
    • Adipose Tissue
    • Bone Marrow
    • Cord Blood
    • Peripheral Blood
  • Process Technology
    • Expansion
    • Formulation
      • Cryopreservation
      • Lyophilization
    • Genetic Modification
      • Non-Viral
      • Viral Vector
    • Isolation
  • End User
    • Contract Manufacturing Org
    • Hospitals
      • Academic Medical Center
      • Community Hospital
    • Research Institutes
    • Specialty Clinics
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Novartis AG
  • Gilead Sciences, Inc.
  • Bristol-Myers Squibb Company
  • bluebird bio, Inc.
  • Legend Biotech Corporation
  • Autolus Therapeutics plc
  • Adaptimmune Therapeutics plc
  • MaxCyte, Inc.
  • Celyad Oncology SA
  • Poseida Therapeutics, Inc.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Autologous Cell Therapies Market, by Therapy Area
8.1. Introduction
8.2. Dermatology
8.2.1. Wound Healing
8.3. Immunology
8.3.1. Autoimmune Diseases
8.3.2. Transplant Rejection
8.4. Neurology
8.4.1. Parkinsons Disease
8.4.2. Spinal Cord Injury
8.5. Oncology
8.5.1. Hematological Cancer
8.5.2. Solid Tumors
8.6. Orthopedics
8.6.1. Bone Regeneration
8.6.2. Cartilage Repair
9. Autologous Cell Therapies Market, by Cell Type
9.1. Introduction
9.2. Dendritic Cells
9.3. Nk Cells
9.3.1. Car Nk
9.4. Stem Cells
9.4.1. Hematopoietic Stem
9.4.2. Ipsc
9.4.3. Mesenchymal Stem
9.5. T Cells
9.5.1. Car T
9.5.2. Tcr T
10. Autologous Cell Therapies Market, by Source Tissue
10.1. Introduction
10.2. Adipose Tissue
10.3. Bone Marrow
10.4. Cord Blood
10.5. Peripheral Blood
11. Autologous Cell Therapies Market, by Process Technology
11.1. Introduction
11.2. Expansion
11.3. Formulation
11.3.1. Cryopreservation
11.3.2. Lyophilization
11.4. Genetic Modification
11.4.1. Non-Viral
11.4.2. Viral Vector
11.5. Isolation
12. Autologous Cell Therapies Market, by End User
12.1. Introduction
12.2. Contract Manufacturing Org
12.3. Hospitals
12.3.1. Academic Medical Center
12.3.2. Community Hospital
12.4. Research Institutes
12.5. Specialty Clinics
13. Americas Autologous Cell Therapies Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Autologous Cell Therapies Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Autologous Cell Therapies Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Novartis AG
16.3.2. Gilead Sciences, Inc.
16.3.3. Bristol-Myers Squibb Company
16.3.4. bluebird bio, Inc.
16.3.5. Legend Biotech Corporation
16.3.6. Autolus Therapeutics plc
16.3.7. Adaptimmune Therapeutics plc
16.3.8. MaxCyte, Inc.
16.3.9. Celyad Oncology SA
16.3.10. Poseida Therapeutics, Inc.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. AUTOLOGOUS CELL THERAPIES MARKET MULTI-CURRENCY
FIGURE 2. AUTOLOGOUS CELL THERAPIES MARKET MULTI-LANGUAGE
FIGURE 3. AUTOLOGOUS CELL THERAPIES MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY THERAPY AREA, 2024 VS 2030 (%)
FIGURE 8. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY THERAPY AREA, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY CELL TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY CELL TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE TISSUE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE TISSUE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY PROCESS TECHNOLOGY, 2024 VS 2030 (%)
FIGURE 14. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY PROCESS TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. AUTOLOGOUS CELL THERAPIES MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. AUTOLOGOUS CELL THERAPIES MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. AUTOLOGOUS CELL THERAPIES MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY DERMATOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY WOUND HEALING, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY DERMATOLOGY, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY IMMUNOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY TRANSPLANT REJECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY PARKINSONS DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SPINAL CORD INJURY, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY HEMATOLOGICAL CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY ORTHOPEDICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY BONE REGENERATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY CARTILAGE REPAIR, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY ORTHOPEDICS, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY DENDRITIC CELLS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY NK CELLS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY CAR NK, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY NK CELLS, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY STEM CELLS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY HEMATOPOIETIC STEM, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY IPSC, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY MESENCHYMAL STEM, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY STEM CELLS, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY T CELLS, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY CAR T, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY TCR T, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY T CELLS, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE TISSUE, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY ADIPOSE TISSUE, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY BONE MARROW, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY CORD BLOOD, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY PERIPHERAL BLOOD, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY PROCESS TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY EXPANSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY FORMULATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY CRYOPRESERVATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY LYOPHILIZATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY GENETIC MODIFICATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY NON-VIRAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY VIRAL VECTOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY GENETIC MODIFICATION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY ISOLATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY CONTRACT MANUFACTURING ORG, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY ACADEMIC MEDICAL CENTER, BY REGION, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY COMMUNITY HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
TABLE 65. AMERICAS AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY DERMATOLOGY, 2018-2030 (USD MILLION)
TABLE 66. AMERICAS AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
TABLE 67. AMERICAS AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 68. AMERICAS AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 69. AMERICAS AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY ORTHOPEDICS, 2018-2030 (USD MILLION)
TABLE 70. AMERICAS AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
TABLE 71. AMERICAS AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY NK CELLS, 2018-2030 (USD MILLION)
TABLE 72. AMERICAS AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY STEM CELLS, 2018-2030 (USD MILLION)
TABLE 73. AMERICAS AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY T CELLS, 2018-2030 (USD MILLION)
TABLE 74. AMERICAS AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE TISSUE, 2018-2030 (USD MILLION)
TABLE 75. AMERICAS AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY PROCESS TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 76. AMERICAS AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 77. AMERICAS AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY GENETIC MODIFICATION, 2018-2030 (USD MILLION)
TABLE 78. AMERICAS AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 79. AMERICAS AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 80. AMERICAS AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 81. UNITED STATES AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
TABLE 82. UNITED STATES AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY DERMATOLOGY, 2018-2030 (USD MILLION)
TABLE 83. UNITED STATES AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
TABLE 84. UNITED STATES AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 85. UNITED STATES AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 86. UNITED STATES AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY ORTHOPEDICS, 2018-2030 (USD MILLION)
TABLE 87. UNITED STATES AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
TABLE 88. UNITED STATES AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY NK CELLS, 2018-2030 (USD MILLION)
TABLE 89. UNITED STATES AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY STEM CELLS, 2018-2030 (USD MILLION)
TABLE 90. UNITED STATES AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY T CELLS, 2018-2030 (USD MILLION)
TABLE 91. UNITED STATES AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE TISSUE, 2018-2030 (USD MILLION)
TABLE 92. UNITED STATES AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY PROCESS TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 93. UNITED STATES AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 94. UNITED STATES AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY GENETIC MODIFICATION, 2018-2030 (USD MILLION)
TABLE 95. UNITED STATES AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 96. UNITED STATES AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 97. UNITED STATES AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 98. CANADA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
TABLE 99. CANADA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY DERMATOLOGY, 2018-2030 (USD MILLION)
TABLE 100. CANADA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
TABLE 101. CANADA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 102. CANADA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 103. CANADA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY ORTHOPEDICS, 2018-2030 (USD MILLION)
TABLE 104. CANADA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
TABLE 105. CANADA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY NK CELLS, 2018-2030 (USD MILLION)
TABLE 106. CANADA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY STEM CELLS, 2018-2030 (USD MILLION)
TABLE 107. CANADA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY T CELLS, 2018-2030 (USD MILLION)
TABLE 108. CANADA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE TISSUE, 2018-2030 (USD MILLION)
TABLE 109. CANADA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY PROCESS TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 110. CANADA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 111. CANADA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY GENETIC MODIFICATION, 2018-2030 (USD MILLION)
TABLE 112. CANADA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 113. CANADA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 114. MEXICO AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
TABLE 115. MEXICO AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY DERMATOLOGY, 2018-2030 (USD MILLION)
TABLE 116. MEXICO AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
TABLE 117. MEXICO AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 118. MEXICO AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 119. MEXICO AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY ORTHOPEDICS, 2018-2030 (USD MILLION)
TABLE 120. MEXICO AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
TABLE 121. MEXICO AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY NK CELLS, 2018-2030 (USD MILLION)
TABLE 122. MEXICO AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY STEM CELLS, 2018-2030 (USD MILLION)
TABLE 123. MEXICO AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY T CELLS, 2018-2030 (USD MILLION)
TABLE 124. MEXICO AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE TISSUE, 2018-2030 (USD MILLION)
TABLE 125. MEXICO AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY PROCESS TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 126. MEXICO AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 127. MEXICO AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY GENETIC MODIFICATION, 2018-2030 (USD MILLION)
TABLE 128. MEXICO AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 129. MEXICO AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 130. BRAZIL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
TABLE 131. BRAZIL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY DERMATOLOGY, 2018-2030 (USD MILLION)
TABLE 132. BRAZIL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
TABLE 133. BRAZIL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 134. BRAZIL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 135. BRAZIL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY ORTHOPEDICS, 2018-2030 (USD MILLION)
TABLE 136. BRAZIL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
TABLE 137. BRAZIL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY NK CELLS, 2018-2030 (USD MILLION)
TABLE 138. BRAZIL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY STEM CELLS, 2018-2030 (USD MILLION)
TABLE 139. BRAZIL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY T CELLS, 2018-2030 (USD MILLION)
TABLE 140. BRAZIL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE TISSUE, 2018-2030 (USD MILLION)
TABLE 141. BRAZIL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY PROCESS TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 142. BRAZIL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 143. BRAZIL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY GENETIC MODIFICATION, 2018-2030 (USD MILLION)
TABLE 144. BRAZIL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 145. BRAZIL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 146. ARGENTINA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
TABLE 147. ARGENTINA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY DERMATOLOGY, 2018-2030 (USD MILLION)
TABLE 148. ARGENTINA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
TABLE 149. ARGENTINA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 150. ARGENTINA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 151. ARGENTINA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY ORTHOPEDICS, 2018-2030 (USD MILLION)
TABLE 152. ARGENTINA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
TABLE 153. ARGENTINA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY NK CELLS, 2018-2030 (USD MILLION)
TABLE 154. ARGENTINA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY STEM CELLS, 2018-2030 (USD MILLION)
TABLE 155. ARGENTINA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY T CELLS, 2018-2030 (USD MILLION)
TABLE 156. ARGENTINA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE TISSUE, 2018-2030 (USD MILLION)
TABLE 157. ARGENTINA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY PROCESS TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 158. ARGENTINA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 159. ARGENTINA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY GENETIC MODIFICATION, 2018-2030 (USD MILLION)
TABLE 160. ARGENTINA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 161. ARGENTINA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 162. EUROPE, MIDDLE EAST & AFRICA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
TABLE 163. EUROPE, MIDDLE EAST & AFRICA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY DERMATOLOGY, 2018-2030 (USD MILLION)
TABLE 164. EUROPE, MIDDLE EAST & AFRICA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
TABLE 165. EUROPE, MIDDLE EAST & AFRICA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 166. EUROPE, MIDDLE EAST & AFRICA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 167. EUROPE, MIDDLE EAST & AFRICA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY ORTHOPEDICS, 2018-2030 (USD MILLION)
TABLE 168. EUROPE, MIDDLE EAST & AFRICA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
TABLE 169. EUROPE, MIDDLE EAST & AFRICA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY NK CELLS, 2018-2030 (USD MILLION)
TABLE 170. EUROPE, MIDDLE EAST & AFRICA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY STEM CELLS, 2018-2030 (USD MILLION)
TABLE 171. EUROPE, MIDDLE EAST & AFRICA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY T CELLS, 2018-2030 (USD MILLION)
TABLE 172. EUROPE, MIDDLE EAST & AFRICA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE TISSUE, 2018-2030 (USD MILLION)
TABLE 173. EUROPE, MIDDLE EAST & AFRICA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY PROCESS TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 174. EUROPE, MIDDLE EAST & AFRICA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 175. EUROPE, MIDDLE EAST & AFRICA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY GENETIC MODIFICATION, 2018-2030 (USD MILLION)
TABLE 176. EUROPE, MIDDLE EAST & AFRICA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 177. EUROPE, MIDDLE EAST & AFRICA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 178. EUROPE, MIDDLE EAST & AFRICA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 179. UNITED KINGDOM AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
TABLE 180. UNITED KINGDOM AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY DERMATOLOGY, 2018-2030 (USD MILLION)
TABLE 181. UNITED KINGDOM AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
TABLE 182. UNITED KINGDOM AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 183. UNITED KINGDOM AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 184. UNITED KINGDOM AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY ORTHOPEDICS, 2018-2030 (USD MILLION)
TABLE 185. UNITED KINGDOM AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
TABLE 186. UNITED KINGDOM AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY NK CELLS, 2018-2030 (USD MILLION)
TABLE 187. UNITED KINGDOM AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY STEM CELLS, 2018-2030 (USD MILLION)
TABLE 188. UNITED KINGDOM AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY T CELLS, 2018-2030 (USD MILLION)
TABLE 189. UNITED KINGDOM AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE TISSUE, 2018-2030 (USD MILLION)
TABLE 190. UNITED KINGDOM AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY PROCESS TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 191. UNITED KINGDOM AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 192. UNITED KINGDOM AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY GENETIC MODIFICATION, 2018-2030 (USD MILLION)
TABLE 193. UNITED KINGDOM AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 194. UNITED KINGDOM AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 195. GERMANY AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
TABLE 196. GERMANY AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY DERMATOLOGY, 2018-2030 (USD MILLION)
TABLE 197. GERMANY AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
TABLE 198. GERMANY AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 199. GERMANY AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 200. GERMANY AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY ORTHOPEDICS, 2018-2030 (USD MILLION)
TABLE 201. GERMANY AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
TABLE 202. GERMANY AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY NK CELLS, 2018-2030 (USD MILLION)
TABLE 203. GERMANY AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY STEM CELLS, 2018-2030 (USD MILLION)
TABLE 204. GERMANY AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY T CELLS, 2018-2030 (USD MILLION)
TABLE 205. GERMANY AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE TISSUE, 2018-2030 (USD MILLION)
TABLE 206. GERMANY AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY PROCESS TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 207. GERMANY AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 208. GERMANY AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY GENETIC MODIFICATION, 2018-2030 (USD MILLION)
TABLE 209. GERMANY AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 210. GERMANY AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 211. FRANCE AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
TABLE 212. FRANCE AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY DERMATOLOGY, 2018-2030 (USD MILLION)
TABLE 213. FRANCE AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
TABLE 214. FRANCE AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 215. FRANCE AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 216. FRANCE AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY ORTHOPEDICS, 2018-2030 (USD MILLION)
TABLE 217. FRANCE AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
TABLE 218. FRANCE AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY NK CELLS, 2018-2030 (USD MILLION)
TABLE 219. FRANCE AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY STEM CELLS, 2018-2030 (USD MILLION)
TABLE 220. FRANCE AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY T CELLS, 2018-2030 (USD MILLION)
TABLE 221. FRANCE AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE TISSUE, 2018-2030 (USD MILLION)
TABLE 222. FRANCE AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY PROCESS TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 223. FRANCE AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 224. FRANCE AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY GENETIC MODIFICATION, 2018-2030 (USD MILLION)
TABLE 225. FRANCE AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 226. FRANCE AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 227. RUSSIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
TABLE 228. RUSSIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY DERMATOLOGY, 2018-2030 (USD MILLION)
TABLE 229. RUSSIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
TABLE 230. RUSSIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 231. RUSSIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 232. RUSSIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY ORTHOPEDICS, 2018-2030 (USD MILLION)
TABLE 233. RUSSIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
TABLE 234. RUSSIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY NK CELLS, 2018-2030 (USD MILLION)
TABLE 235. RUSSIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY STEM CELLS, 2018-2030 (USD MILLION)
TABLE 236. RUSSIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY T CELLS, 2018-2030 (USD MILLION)
TABLE 237. RUSSIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE TISSUE, 2018-2030 (USD MILLION)
TABLE 238. RUSSIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY PROCESS TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 239. RUSSIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 240. RUSSIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY GENETIC MODIFICATION, 2018-2030 (USD MILLION)
TABLE 241. RUSSIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 242. RUSSIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 243. ITALY AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
TABLE 244. ITALY AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY DERMATOLOGY, 2018-2030 (USD MILLION)
TABLE 245. ITALY AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
TABLE 246. ITALY AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 247. ITALY AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 248. ITALY AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY ORTHOPEDICS, 2018-2030 (USD MILLION)
TABLE 249. ITALY AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
TABLE 250. ITALY AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY NK CELLS, 2018-2030 (USD MILLION)
TABLE 251. ITALY AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY STEM CELLS, 2018-2030 (USD MILLION)
TABLE 252. ITALY AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY T CELLS, 2018-2030 (USD MILLION)
TABLE 253. ITALY AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE TISSUE, 2018-2030 (USD MILLION)
TABLE 254. ITALY AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY PROCESS TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 255. ITALY AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 256. ITALY AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY GENETIC MODIFICATION, 2018-2030 (USD MILLION)
TABLE 257. ITALY AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 258. ITALY AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 259. SPAIN AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
TABLE 260. SPAIN AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY DERMATOLOGY, 2018-2030 (USD MILLION)
TABLE 261. SPAIN AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
TABLE 262. SPAIN AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 263. SPAIN AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 264. SPAIN AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY ORTHOPEDICS, 2018-2030 (USD MILLION)
TABLE 265. SPAIN AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
TABLE 266. SPAIN AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY NK CELLS, 2018-2030 (USD MILLION)
TABLE 267. SPAIN AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY STEM CELLS, 2018-2030 (USD MILLION)
TABLE 268. SPAIN AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY T CELLS, 2018-2030 (USD MILLION)
TABLE 269. SPAIN AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE TISSUE, 2018-2030 (USD MILLION)
TABLE 270. SPAIN AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY PROCESS TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 271. SPAIN AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 272. SPAIN AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY GENETIC MODIFICATION, 2018-2030 (USD MILLION)
TABLE 273. SPAIN AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 274. SPAIN AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 275. UNITED ARAB EMIRATES AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
TABLE 276. UNITED ARAB EMIRATES AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY DERMATOLOGY, 2018-2030 (USD MILLION)
TABLE 277. UNITED ARAB EMIRATES AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
TABLE 278. UNITED ARAB EMIRATES AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 279. UNITED ARAB EMIRATES AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 280. UNITED ARAB EMIRATES AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY ORTHOPEDICS, 2018-2030 (USD MILLION)
TABLE 281. UNITED ARAB EMIRATES AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
TABLE 282. UNITED ARAB EMIRATES AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY NK CELLS, 2018-2030 (USD MILLION)
TABLE 283. UNITED ARAB EMIRATES AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY STEM CELLS, 2018-2030 (USD MILLION)
TABLE 284. UNITED ARAB EMIRATES AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY T CELLS, 2018-2030 (USD MILLION)
TABLE 285. UNITED ARAB EMIRATES AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE TISSUE, 2018-2030 (USD MILLION)
TABLE 286. UNITED ARAB EMIRATES AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY PROCESS TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 287. UNITED ARAB EMIRATES AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 288. UNITED ARAB EMIRATES AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY GENETIC MODIFICATION, 2018-2030 (USD MILLION)
TABLE 289. UNITED ARAB EMIRATES AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 290. UNITED ARAB EMIRATES AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 291. SAUDI ARABIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
TABLE 292. SAUDI ARABIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY DERMATOLOGY, 2018-2030 (USD MILLION)
TABLE 293. SAUDI ARABIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
TABLE 294. SAUDI ARABIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 295. SAUDI ARABIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 296. SAUDI ARABIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY ORTHOPEDICS, 2018-2030 (USD MILLION)
TABLE 297. SAUDI ARABIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
TABLE 298. SAUDI ARABIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY NK CELLS, 2018-2030 (USD MILLION)
TABLE 299. SAUDI ARABIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY STEM CELLS, 2018-2030 (USD MILLION)
TABLE 300. SAUDI ARABIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY T CELLS, 2018-2030 (USD MILLION)
TABLE 301. SAUDI ARABIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE TISSUE, 2018-2030 (USD MILLION)
TABLE 302. SAUDI ARABIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY PROCESS TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 303. SAUDI ARABIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 304. SAUDI ARABIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY GENETIC MODIFICATION, 2018-2030 (USD MILLION)
TABLE 305. SAUDI ARABIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 306. SAUDI ARABIA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 307. SOUTH AFRICA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
TABLE 308. SOUTH AFRICA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY DERMATOLOGY, 2018-2030 (USD MILLION)
TABLE 309. SOUTH AFRICA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
TABLE 310. SOUTH AFRICA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 311. SOUTH AFRICA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 312. SOUTH AFRICA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY ORTHOPEDICS, 2018-2030 (USD MILLION)
TABLE 313. SOUTH AFRICA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
TABLE 314. SOUTH AFRICA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY NK CELLS, 2018-2030 (USD MILLION)
TABLE 315. SOUTH AFRICA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY STEM CELLS, 2018-2030 (USD MILLION)
TABLE 316. SOUTH AFRICA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY T CELLS, 2018-2030 (USD MILLION)
TABLE 317. SOUTH AFRICA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY SOURCE TISSUE, 2018-2030 (USD MILLION)
TABLE 318. SOUTH AFRICA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY PROCESS TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 319. SOUTH AFRICA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 320. SOUTH AFRICA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY GENETIC MODIFICATION, 2018-2030 (USD MILLION)
TABLE 321. SOUTH AFRICA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 322. SOUTH AFRICA AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 323. DENMARK AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY THERAPY AREA, 2018-2030 (USD MILLION)
TABLE 324. DENMARK A

Companies Mentioned

The companies profiled in this Autologous Cell Therapies market report include:
  • Novartis AG
  • Gilead Sciences, Inc.
  • Bristol-Myers Squibb Company
  • bluebird bio, Inc.
  • Legend Biotech Corporation
  • Autolus Therapeutics plc
  • Adaptimmune Therapeutics plc
  • MaxCyte, Inc.
  • Celyad Oncology SA
  • Poseida Therapeutics, Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages188
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 10.62 Billion
Forecasted Market Value ( USD ) by 2030 $ 20.99 Billion
Compound Annual Growth Rate14.6%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Pharmaceutical Industry Outlook, 2024 - Product Image

Pharmaceutical Industry Outlook, 2024

  • Report
  • 86 Pages
  • Global
From
Pharmaceuticals North America (NAFTA) Industry Guide 2019-2028 - Product Image

Pharmaceuticals North America (NAFTA) Industry Guide 2019-2028

  • Report
  • 286 Pages
  • North America
From
Asia-Pacific Pharmaceutical Industry Outlook 2023 - Product Image

Asia-Pacific Pharmaceutical Industry Outlook 2023

  • Report
  • 77 Pages
  • Asia Pacific
From
Pharmaceutical Validation Services Market - Global Industry Size, Share, Trends, Opportunity and Forecast, 2020-2030F - Product Image

Pharmaceutical Validation Services Market - Global Industry Size, Share, Trends, Opportunity and Forecast, 2020-2030F

  • Report
  • 187 Pages
  • Global
From
Cell Therapy - Global Strategic Business Report - Product Image

Cell Therapy - Global Strategic Business Report

  • Report
  • 263 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.